95%
Cell death
100%
Tumor growth inhibition
0
Toxicity signals across several in vivo studies
Powerful medicines.
A fundamental delivery challenge
A therapeutic can only work where it reaches the right cells. OncoXome is developing a proprietary, engineered plant-derived vesicle platform to address that barrier.
Oral delivery
A different route for advanced therapeutics
Multiple payloads
CRISPR Cas9
siRNA
mRNA
Oncology first
Colorectal cancer anchors our development
WHAT WE HAVE SHOWN
Oral. Tumor targeted. Silenced. No toxicity.
In vivo mouse studies
↗ Preclinical efficacy signal
Antitumor activity observed with CRISPR-Cas9 in mouse models.
↗ Liver and gut bypass
A carrier that crosses the gut and reaches solid tumors is not only a colorectal asset. It is an oral route for every nucleic-acid medicine currently stuck with infusion.
↗ External evaluation pathway
LOI with Wacker to test the delivery system. Evaluation is distinct from independent validation.
↗ Production, loading & storage
Reproducible production established; cargo loading and storage capabilities developed.
THE ROUND
$10M to reach value inflection point: IND filing
USE OF FUNDS
[16%] Full efficacy and safety study
[18%] GMP Manufacturing
[15%] GLP Toxicology
[15%] Pre IND meeting and IND submission
[36%] Personnel and admin